Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab.
about
Translating transitions - how to decipher peripheral human B cell developmentTherapeutic approaches for celiac diseaseResponse to rituximab in patients with rheumatoid arthritis in different compartments of the immune system.Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapyB cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy.Shifting Focus in the Therapeutics of Immunobullous Disease.Novel therapies for coeliac diseaseRestrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritisThe anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression.Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapyThe protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity.Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies.Advances in the treatment of coeliac disease: an immunopathogenic perspective.Celiac disease: the search for adjunctive or alternative therapies.Celiac disease 2015 update: new therapies.Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases.Plasmablasts with a mucosal phenotype contribute to plasmacytosis in SLE.The human intestinal B-cell response.Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.Massive plasmablast response elicited in the acute phase of hantavirus pulmonary syndrome.Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins.Rituximab in early systemic sclerosis.Circulating (CD3(-)CD19(+)CD20(-)IgD(-)CD27(high)CD38(high)) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus.Efficient long-term depletion of CD20+ B cells by rituximab does not affect gut-resident plasma cells.Transitional B Cells and TLR9 Responses Are Defective in Selective IgA Deficiency.Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.A splenic IgM memory subset with antibacterial specificities is sustained from persistent mucosal responses
P2860
Q26799037-6DCCE32A-7879-4455-B6D0-BCA6B6B6D0AFQ26825413-90CE0F4A-7915-455C-80CB-227FD1146CA2Q27692640-8063D1EA-E5AF-4420-8F6B-6980B4B0FBE3Q28084913-4EF1422A-D0E2-4829-81CD-B7623A467AF2Q33404838-2DE34F7C-B8DC-4652-9429-56BD61FFD171Q33412584-B570B3CF-48A9-499E-9B7C-FBED4FDD29B7Q33737974-915EF3FE-435A-4FAA-B000-8E00C1DAB761Q34170574-E177760B-B5E3-4F5F-A002-C81F3A96596BQ35744377-880F6200-0D75-40D7-8883-A31CAAFF6618Q36245707-2B3CB902-7378-485C-8B84-A55944E67F8FQ37117624-366775BB-8D63-4EAD-94A9-CCAB10EE09EAQ37630230-638BBF12-CBFE-47EA-84AD-500502378691Q38071110-A8745653-51F3-41FF-9499-ECE743E0977EQ38097170-86D1E6F3-E123-4B05-AD10-1D4C8E4E0D53Q38126789-37C40646-D83A-4A73-9502-89AD45798076Q38184586-72B562D5-56FE-42F3-9827-73337A2EE239Q38416745-76ADD064-64D5-4AE1-A849-BA92C09BCB45Q38673420-A44A930B-36BE-4E4E-B304-36130228048DQ38722252-E5F92869-1BED-40E9-8927-25FD8EEE4745Q38909459-9C7F7AAD-5390-4820-B6C5-4015FC2DBE09Q39218839-31698D3B-10F4-4B71-8F24-34FF8D803F47Q40364442-9075B1A9-4D8D-4FF2-9C44-B76A784341C9Q40610167-A14E955A-2AA8-4798-BA44-61D8CE0C8AFAQ41544232-1B49A006-4F4A-4EC7-BFAA-FEF42A2BAE17Q41817501-1F17446E-D612-4985-A32E-667CC884594EQ42464517-AAC9B49C-922F-4B32-B1B3-4BD17347ED22Q49374267-76C7D36C-CB1F-4739-B49D-01BEFE42FEE8Q55019957-D030F468-BBC8-4187-BB10-5921C29B83C1Q55153722-A8D6628F-1430-4B4A-BDE9-9FB00B148153Q57976581-DCF2249A-DBA6-4E9B-B47C-49210A8CF5AC
P2860
Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Steady-state generation of muc ...... letion therapy with rituximab.
@en
Steady-state generation of muc ...... letion therapy with rituximab.
@nl
type
label
Steady-state generation of muc ...... letion therapy with rituximab.
@en
Steady-state generation of muc ...... letion therapy with rituximab.
@nl
prefLabel
Steady-state generation of muc ...... letion therapy with rituximab.
@en
Steady-state generation of muc ...... letion therapy with rituximab.
@nl
P2093
P1433
P1476
Steady-state generation of muc ...... letion therapy with rituximab.
@en
P2093
Andreas Radbruch
Capucine Daridon
Claudia Giesecke
Daniela Frölich
Eugen Feist
Henrik E Mei
Karin Reiter
Stefanie Schmidt
Thomas Dörner
P304
P356
10.1182/BLOOD-2010-01-266536
P407
P577
2010-09-09T00:00:00Z